{
  "patient_id": "PATIENT_003",
  "drug": "SIMVASTATIN",
  "timestamp": "2026-02-19T13:40:00Z",
  "risk_assessment": {
    "risk_label": "Adjust Dosage",
    "confidence_score": 0.85,
    "severity": "moderate"
  },
  "pharmacogenomic_profile": {
    "primary_gene": "SLCO1B1",
    "diplotype": "*1/*5",
    "phenotype": "IM",
    "detected_variants": [
      {
        "rsid": "rs4149056",
        "ref": "T",
        "alt": "C",
        "genotype": "0/1"
      }
    ]
  },
  "clinical_recommendation": {
    "guideline": "Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy. If simvastatin therapy is warranted, limit dose to <20mg/day or prescribe an alternative statin."
  },
  "llm_generated_explanation": {
    "summary": "Patient has intermediate SLCO1B1 function, leading to a moderate risk of statin-induced myopathy.",
    "biological_mechanism": "The heterozygous variant rs4149056 reduces the transport of simvastatin into the liver. This causes the drug to build up in the bloodstream, increasing the risk of muscle toxicity and myopathy."
  },
  "quality_metrics": {
    "vcf_parsing_success": true,
    "variants_analyzed": 1
  }
}
